“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
HOME > COLUMN
COLUMN
-
Does Your Company Want to Increase Its Diversity?
July 5, 2021
-
5 Lessons in 5 Years from Rocking the Bag
June 17, 2021
-
Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
May 28, 2021
-
Set the Stage for an Exceptional Customer Experience
May 21, 2021
-
Pricing Reform in Japan: How Must Life Science Companies Evolve?
April 23, 2021
-
Do You Attract or Repel Winning Candidates?
April 16, 2021
-
The Future of Customer Engagement in Japan’s Life Science Industry: One Year Post-COVID
March 19, 2021
-
Bring Your A-Game to Your Next Video Call
March 11, 2021
-
What Personal Biases Influence Your Hires?
February 19, 2021
-
Is Your Company Culture Being a Victim of COVID-19?
January 8, 2021
-
It’s the Everyday Leaders Your Organization Needs
December 11, 2020
-
Let’s Be Grateful for the Chaos of the Year That Was
November 18, 2020
-
Empower Smarter Decision Making with Big Data
October 23, 2020
-
5 Improvements when Recruiting Female Employees
September 25, 2020
-
Think Differently for Post-Pandemic Success
August 14, 2020
-
The Crisis That Ignited a Workplace Revolution
July 6, 2020
-
Smart Strategies for Building Your Dream Team
March 17, 2020
-
A Peek into the Digital Pharmaceutical Industry
November 21, 2019
-
Plant the Seeds of Success when Battling a Crisis
September 30, 2019
-
Practice Makes Perfect - Even in Marketing!
August 19, 2019
ページ
Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…